Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06090630 · ClinicalTrials.gov registry record · Early Phase 1
MR Correlated Spectroscopic Imaging for Diagnosing Breast Cancer
A Early Phase 1 study of Breast Carcinoma and Malignant Breast Neoplasm, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 83
- Enrollment target
- 1
- Study location
NCT06090630: Completed Early Phase 1 study of Breast Carcinoma and Malignant Breast Neoplasm, sponsored by Jonsson Comprehensive Cancer Center.
NCT06090630 is a Early Phase 1 study of Breast Carcinoma and Malignant Breast Neoplasm that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 83 participants, below the 770-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06090630, a Early Phase 1 study of Breast Carcinoma and Malignant Breast Neoplasm, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 83 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial studies how well an imaging technique called magnetic resonance (MR) spectroscopic imaging works in identifying breast cancer in women with benign or suspicious areas in the breast. Magnetic resonance imaging (MRI) is a diagnostic tool used to investigate the location of tumors in different organs. Since radiological pictures do not have sufficient information for tumor grades, invasive procedure such as biopsy is performed on patients with breast cancers for diagnosis. Breast tissue contains water, fat, and chemicals known as metabolites. MR spectroscopic imaging may help to characterize the various breast metabolite steady state levels and identify the differences between necrosis and tumor recurrence, which is difficult using radiological procedures such as MRI.
Primary Outcome
ADC maps will be calculated from diffusion weighted (DW) images by using linear regression of logarithmic intensities by using software for combinations of two, three, four, and five DW images with different b values. ADC maps will also be calculated for the remaining combinations of up to 10 evenly distributed b values. In total, 501 value combinations will be automatically processed and analyzed.
Conditions Studied
Interventions
- PROCEDURE Magnetic Resonance Spectroscopic Imaging
- PROCEDURE Diffusion Weighted Imaging
Study Locations (1)
California
- UCLA / Jonsson Comprehensive Cancer Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2017-07-31 |
| Est. Completion | 2023-02-03 |
| Phase | Early Phase 1 |
What the finished NCT06090630 record still lists
NCT06090630 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 83 participants, a relatively small participant target, below the 770-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (89% lower).
The record links to 3 conditions, with Breast Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Magnetic Resonance Spectroscopic Imaging is the first listed.
NCT06090630 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06090630 about?
NCT06090630 is a clinical study titled "MR Correlated Spectroscopic Imaging for Diagnosing Breast Cancer". This trial studies how well an imaging technique called magnetic resonance (MR) spectroscopic imaging works in identifying breast cancer in women with benign or suspicious areas in the breast. Magnetic resonance imaging (MRI) is a diagnostic tool used to investigate the location of tumors in differe...
What is the current status of trial NCT06090630?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 83 participants. The study started on 2017-07-31. Estimated completion is 2023-02-03.
What conditions does trial NCT06090630 study?
This clinical trial studies the following conditions: Breast Carcinoma, Malignant Breast Neoplasm, Benign Breast Neoplasm.
What interventions are being tested in trial NCT06090630?
The interventions under investigation include: Magnetic Resonance Spectroscopic Imaging (PROCEDURE), Diffusion Weighted Imaging (PROCEDURE).
Who is sponsoring clinical trial NCT06090630?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06090630 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06090630's enrollment target sits among peer trials
83 65th of 106 higher than 42 of 106 other Breast Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
3D Ultrasound for the Imaging of Lymph Nodes in Patients With Breast Cancer
RECRUITING · Early Phase 1
-
MUSE-S Headband System for Improving Anxiety and Insomnia Among Breast Cancer Survivors
RECRUITING · Early Phase 1
-
First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide
ACTIVE NOT RECRUITING · Early Phase 1
-
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
ACTIVE NOT RECRUITING · Early Phase 1
-
Surviving Daily Life
RECRUITING
-
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02974647 · 83 participants · Phase 2
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
- NCT03919292 · 83 participants · Phase 1
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
- NCT04626674 · 83 participants · Phase 1
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
- NCT05277168 · 83 participants · Phase 1
A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI